ArticleFrontiers in pharmacology2021
Function of Uric Acid Transporters and Their Inhibitors in Hyperuricaemia.
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Phytochemical compounds for treating hyperuricemia associated with gout: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- A systematic review of single nucleotide polymorphisms affecting allopurinol pharmacokinetics and serum uric acid level.Pharmacogenomics · 2024Pooled it
- Uric acid and glaucoma: a systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- A potential association of SLC2A9 variant rs7442295 with uric acid at baseline and in interaction with iloperidone.The pharmacogenomics journal · 2026Trial
- Risk Factors and Prediction Models for Nonalcoholic Fatty Liver Disease Based on Random Forest.Computational and mathematical methods in medicine · 2022Trial
- Phragmites Communis (Lu Gen) Alleviates Hyperuricemia via Xanthine Oxidase Inhibition and Gut-Microbiota-Mediated Metabolite Urate Transporter Regulation.Pharmaceuticals (Basel, Switzerland) · 2026Article
- ABCG2 transporter: Structural and functional associations with gout (Review).International journal of molecular medicine · 2026Review
- The global landscape of pediatric hyperuricemia research: a bibliometric roadmap to mechanisms, management, and future therapeutics (1997-2024).Translational pediatrics · 2026Article
- Therapeutic Strategies for Hyperuricemia: From Small-Molecule Inhibitors to RNA Therapeutics.ACS pharmacology & translational science · 2026Review
- Paper-based laser-written CoO-graphene biosensor for wireless sweat uric acid detection.Scientific reports · 2026Article
- Renoprotective effects of perennial ryegrass attenuate UA mediated renal damage via modulating gut microbiota and anti-oxidative defense.Poultry science · 2026Article
- Patients' knowledge influences practice via attitudes toward hyperuricaemia: a mediation analysis.Clinical rheumatology · 2026Article
- Translating Data Into Clinical Tools: An Integrative Strategy for Precision Biomarker Identification in Soft Tissue Sarcoma Diagnosis and Prognosis.Cancer informatics · 2026Article
- Oral L-carnitine supplementation lowers serum uric acid and is associated with renal and intestinal urate-handling responses in hyperuricemic mice.Frontiers in nutrition · 2026Article
- Short-term dynamics of serum uric acid and its influencing factors in patients with obesity after laparoscopic sleeve gastrectomy.BMC surgery · 2025Article
- The impact of early pregnancy uric acid on gestational diabetes risk: a prospective cohort study in Northwest China.BMC pregnancy and childbirth · 2025Article
- Dandelion Leaf Aqueous Extract Relieves Hyperuricemia and Its Complications via Modulating Uric Acid Metabolism, Renal Inflammation, and Gut Microbes.Foods (Basel, Switzerland) · 2025Article
- Analysis of risk factors associated with metabolic-associated fatty liver disease from Suzhong Region, China: a cross-sectional study.BMJ open · 2025Article
- The Role of the Intestinal Microbiome in the Pathogenesis and Treatment of Hyperuricemia: A Review.Food science & nutrition · 2025Review
- The SLC-ome of membrane transport: From molecular discovery to physiology and clinical applications.Physiological reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disorders of uric acid metabolism may be associated with pathological processes in many diseases, including diabetes mellitus, cardiovascular disease, and kidney disease. These diseases can further promote uric acid accumulation in the body, leading to a vicious cycle. Preliminary studies have proven many mechanisms such as oxidative stress, lipid metabolism disorders, and rennin angiotensin axis involving in the progression of hyperuricaemia-related diseases. However, there is still lack of effective clinical treatment for hyperuricaemia. According to previous research results, NPT1, NPT4, OAT1, OAT2, OAT3, OAT4, URAT1, GLUT9, ABCG2, PDZK1, these urate transports are closely related to serum uric acid level. Targeting at urate transporters and urate-lowering drugs can enhance our understanding of hyperuricaemia and hyperuricaemia-related diseases. This review may put forward essential references or cross references to be contributed to further elucidate traditional and novel urate-lowering drugs benefits as well as provides theoretical support for the scientific research on hyperuricemia and related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.